Compare EVAX & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVAX | ENSC |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.9M | 1.7M |
| IPO Year | 2020 | N/A |
| Metric | EVAX | ENSC |
|---|---|---|
| Price | $3.97 | $0.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | 33.7K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $55.01 |
| Revenue Next Year | $328.20 | $1,033.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.62 | $0.23 |
| 52 Week High | $12.15 | $2.75 |
| Indicator | EVAX | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 30.68 |
| Support Level | $2.76 | N/A |
| Resistance Level | $4.65 | $0.44 |
| Average True Range (ATR) | 0.29 | 0.04 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 4.22 | 21.28 |
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.